Project Flyer

print version
'Cancer Drug Toxicity' image

Clinically approved drugs which prevent blood vessel formation and thereby restrict blood flow to cancer cells can perform a vital role in blocking tumour growth and cancer spread. However, a major consequence of the recent progress in targeted medicine has been the toxic side effects which can occur as a result. AngioTox aims to understand the mechanisms underlying toxicity that are associated with angiogenesis inhibitor drugs. The ultimate goal is to identify an AngioTox Safety Panel of toxicologic markers to facilitate improved screening of angiogenesis inhibitor toxicologic parameters, inform clinical drug dosing regimens, facilitate the development of more specific and potent angiogenesis inhibitors and significantly improve patient care.

Attached Documents

PDF icon Project Flyer (Angiotox_brochure_27-02-13.pdf | 716 kB)